aminoimidazole carboxamide has been researched along with arsenic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lewitt, MS | 1 |
| Chen, L; Han, F; Qu, H; Ren, L; Yan, H; Yang, S | 1 |
2 other study(ies) available for aminoimidazole carboxamide and arsenic
| Article | Year |
|---|---|
Stimulation of IGF-binding protein-1 secretion by AMP-activated protein kinase.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Culture Media, Conditioned; Dexamethasone; Dose-Response Relationship, Drug; Drug Antagonism; Glucocorticoids; Insulin; Insulin Antagonists; Insulin-Like Growth Factor Binding Protein 1; Multienzyme Complexes; Oxides; Protein Serine-Threonine Kinases; Rats; Ribonucleotides; Signal Transduction; Tumor Cells, Cultured | 2001 |
Combination therapy with 5-amino-4-imidazolecarboxamide riboside and arsenic trioxide in acute myeloid leukemia cells involving AMPK/TSC2/mTOR pathway.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; HL-60 Cells; Humans; Hypoglycemic Agents; Leukemia, Myeloid, Acute; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Ribonucleotides; Signal Transduction; TOR Serine-Threonine Kinases; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins | 2013 |